Latitude Initiates Two New Collaboration Studies For PG Depot

Latitude (LPI) has initiated two new collaboration studies for its Phospholipid Gel (PG) Depot drug delivery platform.

The company said that the new studies bring the total to seven feasibility/license agreements, that are applying the PG Depot to deliver small molecules, peptides, and proteins for pain, metabolic disease, anti-bacterial, and cardiovascular applications.

Andrew Chen, president of LPI, said: “Our newest feasibility studies represent a growing validation of our PG Depot technology. Like our ongoing collaborations, the new programs aim to transform a cumbersome routine of multiple injections each day into a convenient once-daily or once-weekly format.”

“Both pharma and biotech companies definitely see high value in simplifying parenteral drug administration and extending or resurrecting IP protection through novel delivery technology. The protein-friendly nature of the PG Depot will create many opportunities to convert biologics from daily to weekly injections,” he added.